{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:17Z","timestamp":1790657777615,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03702-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:05:08Z","timestamp":1783569908000},"page":"4380-4394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0114-1342","authenticated-orcid":false,"given":"Anna Geraldina","family":"Pendrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennyfer Alejandra","family":"Rivera Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Alberto","family":"Alvarez Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eblin Jackeline","family":"R\u00edos Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda Mar\u00eda","family":"Fernandez Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier Francisco","family":"Sevilla Martir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"Suppl 1","key":"3702_CR1","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/oby.70029","volume":"33","author":"A Pendrey","year":"2025","unstructured":"Pendrey A, Sevilla-Martir J. Antiobesity medications for older adults\u2014the new, the good, the bad, and the unknown. Obesity (Silver Spring). 2025;33(Suppl 1):S57\u201373. https:\/\/doi.org\/10.1002\/oby.70029.","journal-title":"Obesity (Silver Spring)."},{"issue":"2","key":"3702_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00125-003-1053-4","volume":"46","author":"G Fr\u00fchbeck","year":"2003","unstructured":"Fr\u00fchbeck G, G\u00f3mez-Ambrosi J. Control of body weight: a physiologic and transgenic perspective. Diabetologia. 2003;46(2):143\u201372. https:\/\/doi.org\/10.1007\/s00125-003-1053-4.","journal-title":"Diabetologia."},{"key":"3702_CR3","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 13. Older adults: Standards of Care in Diabetes\u20142026. Diabetes Care. 2026;49(Suppl\u202f1):S277-S296. https:\/\/doi.org\/10.2337\/dc26-S013","DOI":"10.2337\/dc26-S013"},{"issue":"10","key":"3702_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnha.2025.100652","volume":"29","author":"K Prokopidis","year":"2025","unstructured":"Prokopidis K, Daly RM, Suetta C. Weighing the risk of GLP-1 treatment in older adults: should we be concerned about sarcopenic obesity? J Nutr Health Aging. 2025;29(10):100652. https:\/\/doi.org\/10.1016\/j.jnha.2025.100652.","journal-title":"J Nutr Health Aging."},{"issue":"1","key":"3702_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11357-016-9884-3","volume":"38","author":"M Jura","year":"2016","unstructured":"Jura M, Kozak LP. Obesity and related consequences to ageing. Age (Dordr). 2016;38(1):23. https:\/\/doi.org\/10.1007\/s11357-016-9884-3.","journal-title":"Age (Dordr)."},{"key":"3702_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ajem.2024.01.010","volume":"78","author":"B Long","year":"2024","unstructured":"Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: a review for emergency clinicians. Am J Emerg Med. 2024;78:89\u201394. https:\/\/doi.org\/10.1016\/j.ajem.2024.01.010.","journal-title":"Am J Emerg Med."},{"issue":"1\u20132","key":"3702_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1\u20132):8\u201323. https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00022.x.","journal-title":"J Diabetes Investig."},{"key":"3702_CR8","volume":"31","author":"SA Beshir","year":"2023","unstructured":"Beshir SA, Elnour AA, Soorya A, Mohamed AP, Goh SSL, Hussain N, et al. Pharmacologic management of obesity: current and emerging therapies. Saudi Pharm J. 2023;31:101757.","journal-title":"Saudi Pharm J."},{"issue":"1","key":"3702_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"key":"3702_CR10","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized"},{"key":"3702_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","volume":"49","author":"H Henney","year":"2025","unstructured":"Henney H, Wilding JPH, Alam U, et al. Obesity pharmacotherapy in older adults: a narrative review of evidence. Int J Obes (Lond). 2025;49:369\u201380. https:\/\/doi.org\/10.1038\/s41366-024-01529-z.","journal-title":"Int J Obes (Lond)."},{"issue":"6","key":"3702_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/M18-1569","volume":"170","author":"MP Gilbert","year":"2019","unstructured":"Gilbert MP, Bain SC, Franek E, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann Intern Med. 2019;170(6):423\u20136. https:\/\/doi.org\/10.7326\/M18-1569.","journal-title":"Ann Intern Med."},{"issue":"9","key":"3702_CR13","first-page":"1","volume":"70","author":"M Heron","year":"2021","unstructured":"Heron M. Deaths: leading causes for 2019. Natl Vital Stat Rep. 2021;70(9):1\u2013114.","journal-title":"Natl Vital Stat Rep."},{"issue":"11","key":"3702_CR14","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47(11):1873\u201388. https:\/\/doi.org\/10.2337\/dci24-0003.","journal-title":"Diabetes Care"},{"issue":"24","key":"3702_CR15","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"2","key":"3702_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"5","key":"3702_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12684","volume":"14","author":"A Gavras","year":"2024","unstructured":"Gavras A, Batsis JA. Medical weight loss in older persons with obesity. Clin Obes. 2024;14(5):e12684. https:\/\/doi.org\/10.1111\/cob.12684.","journal-title":"Clin Obes"},{"issue":"4","key":"3702_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/87551225221092681","volume":"38","author":"A Fornes","year":"2022","unstructured":"Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022;38(4):239\u201346. https:\/\/doi.org\/10.1177\/87551225221092681.","journal-title":"J Pharm Technol"},{"issue":"10278","key":"3702_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"issue":"14","key":"3702_CR20","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403\u201313. https:\/\/doi.org\/10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"issue":"14","key":"3702_CR21","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA. 2021;325(14):1414\u201325. https:\/\/doi.org\/10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"issue":"10","key":"3702_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391. https:\/\/doi.org\/10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"9","key":"3702_CR23","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1111\/dom.13331","volume":"20","author":"M Warren","year":"2018","unstructured":"Warren M, Chaykin L, Trachtenbarg D, Nayak G, Wijayasinghe N, Cariou B. Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1\u20135 trials. Diabetes Obes Metab. 2018;20(9):2291\u20137. https:\/\/doi.org\/10.1111\/dom.13331.","journal-title":"Diabetes Obes Metab."},{"key":"3702_CR24","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.23.03985-4","author":"DE Garcia","year":"2023","unstructured":"Garcia DE, Lucas MD, Perez-Belmonte L, et al. Results of semaglutide in patients older than 70 years: a real-world study of efficacy and safety. Minerva Endocrinol (Torino). 2023. https:\/\/doi.org\/10.23736\/S2724-6507.23.03985-4.","journal-title":"Minerva Endocrinol (Torino)."},{"issue":"8","key":"3702_CR25","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1111\/dom.15081","volume":"25","author":"S Verma","year":"2023","unstructured":"Verma S, David JP, Leiter LA, Michelsen MM, Rasmussen S, Bhatt DL. Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes. Diabetes Obes Metab. 2023;25(8):2388\u201392. https:\/\/doi.org\/10.1111\/dom.15081.","journal-title":"Diabetes Obes Metab."},{"issue":"3","key":"3702_CR26","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, et al. Semaglutide reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442\u201351. https:\/\/doi.org\/10.1111\/dom.13955.","journal-title":"Diabetes Obes Metab"},{"issue":"15","key":"3702_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa2313917.","journal-title":"N Engl J Med"},{"issue":"2","key":"3702_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/jod.jod_16_23","volume":"14","author":"MA Abdalla","year":"2023","unstructured":"Abdalla MA, Soyiri I, Atkin S, Sathyapalan T. Tirzepatide as a novel therapeutic option for patients with type 2 diabetes. J Diabetol. 2023;14(2):65\u201373. https:\/\/doi.org\/10.4103\/jod.jod_16_23.","journal-title":"J Diabetol."},{"issue":"7","key":"3702_CR29","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/oby.24037","volume":"32","author":"O Baser","year":"2024","unstructured":"Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. Obesity (Silver Spring). 2024;32(7):1401\u20139. https:\/\/doi.org\/10.1002\/oby.24037.","journal-title":"Obesity (Silver Spring)."},{"issue":"3","key":"3702_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med."},{"issue":"10402","key":"3702_CR31","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet."},{"issue":"1","key":"3702_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity. JAMA. 2024;331(1):38\u201348. https:\/\/doi.org\/10.1001\/jama.2023.24945.","journal-title":"JAMA."},{"issue":"4","key":"3702_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/dom.14952","volume":"25","author":"A Kiyosue","year":"2023","unstructured":"Kiyosue A, Dunn JP, Cui X, et al. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies. Diabetes Obes Metab. 2023;25(4):1056\u201367. https:\/\/doi.org\/10.1111\/dom.14952.","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"3702_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2410027.","journal-title":"N Engl J Med."},{"key":"3702_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2024.107516","volume":"141","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Bednarik J, Chakladar S, et al. Tirzepatide for the treatment of obstructive sleep apnea: rationale and design of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024;141:107516. https:\/\/doi.org\/10.1016\/j.cct.2024.107516.","journal-title":"Contemp Clin Trials."},{"issue":"9","key":"3702_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.12968\/bjcn.2018.23.9.449","volume":"23","author":"S Brook","year":"2018","unstructured":"Brook S. Nutritional considerations in older adults. Br J Commun Nurs. 2018;23(9):449\u201352. https:\/\/doi.org\/10.12968\/bjcn.2018.23.9.449.","journal-title":"Br J Commun Nurs."},{"key":"3702_CR37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.maturitas.2018.04.001","volume":"112","author":"ME Clegg","year":"2018","unstructured":"Clegg ME, Williams EA. Optimizing nutrition in older people. Maturitas. 2018;112:34\u20138. https:\/\/doi.org\/10.1016\/j.maturitas.2018.04.001.","journal-title":"Maturitas."},{"issue":"2","key":"3702_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.14336\/AD.2021.1006","volume":"13","author":"T Ji","year":"2022","unstructured":"Ji T, Li Y, Ma L. Sarcopenic obesity: an emerging public health problem. Aging Dis. 2022;13(2):379. https:\/\/doi.org\/10.14336\/AD.2021.1006.","journal-title":"Aging Dis."},{"issue":"3","key":"3702_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321\u201335. https:\/\/doi.org\/10.1159\/000521241.","journal-title":"Obes Facts."},{"issue":"9","key":"3702_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","volume":"14","author":"JA Batsis","year":"2018","unstructured":"Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol. 2018;14(9):513\u201337. https:\/\/doi.org\/10.1038\/s41574-018-0062-9.","journal-title":"Nat Rev Endocrinol."},{"issue":"4","key":"3702_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/nu18040632","volume":"18","author":"F Moscucci","year":"2026","unstructured":"Moscucci F, Baratta F, Pastori D, et al. A narrative review on GLP-1 receptor agonists for obesity in older women: maximizing weight loss while preserving lean mass. Nutrients. 2026;18(4):632. https:\/\/doi.org\/10.3390\/nu18040632.","journal-title":"Nutrients."},{"issue":"1","key":"3702_CR42","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/bmjnph-2025-001206","volume":"8","author":"G Mocciaro","year":"2025","unstructured":"Mocciaro G, Capodici A, De Amicis R. GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. BMJ Nutr Prev Health. 2025;8(1):4\u20135. https:\/\/doi.org\/10.1136\/bmjnph-2025-001206.","journal-title":"BMJ Nutr Prev Health."},{"issue":"3","key":"3702_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4415\/ANN_23_03_10","volume":"59","author":"M Jurdana","year":"2023","unstructured":"Jurdana M, \u017diberna L. Sarcopenic obesity and hypertension in elderly patients: a narrative review of pathophysiology and management strategies. Ann Ist Super Sanita. 2023;59(3):231\u20139. https:\/\/doi.org\/10.4415\/ANN_23_03_10. (PubMed PMID: 37712242).","journal-title":"Ann Ist Super Sanita."},{"issue":"1","key":"3702_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.36011\/cpp.2025.7.e1","volume":"7","author":"J Noh","year":"2025","unstructured":"Noh J. Pharmacological management of diabetes in older adults. Cardiovasc Prev Pharmacother. 2025;7(1):13\u201320. https:\/\/doi.org\/10.36011\/cpp.2025.7.e1.","journal-title":"Cardiovasc Prev Pharmacother."},{"issue":"10193","key":"3702_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"issue":"4","key":"3702_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"19","key":"3702_CR47","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"3702_CR48","doi-asserted-by":"publisher","first-page":"117955142110516","DOI":"10.1177\/11795514211051697","volume":"14","author":"D Ja'arah","year":"2021","unstructured":"Ja\u2019arah D, Al Zoubi MS, Abdelhady G, Rabi F, Tambuwala MM. Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia. Clin Med Insights Endocrinol Diabetes. 2021;14:11795514211051696. https:\/\/doi.org\/10.1177\/11795514211051697.","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"issue":"2","key":"3702_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.12788\/fp.0452","volume":"41","author":"E Herron","year":"2024","unstructured":"Herron E, Cencetti J, Matis J. Reducing or discontinuing insulin or sulfonylurea when initiating a glucagon-like peptide-1 agonist. Fed Pract. 2024;41(2):52\u20136. https:\/\/doi.org\/10.12788\/fp.0452.","journal-title":"Fed Pract."},{"key":"3702_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/2040622319862691","volume":"12","author":"OF Onoviran","year":"2019","unstructured":"Onoviran OF, Li D, Toombs Smith S, Raji MA. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis. 2019;12:10. https:\/\/doi.org\/10.1177\/2040622319862691.","journal-title":"Ther Adv Chronic Dis."},{"key":"3702_CR51","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5389209","author":"L Fore Williams","year":"2025","unstructured":"Fore Williams L, Purcell M. Anti-obesity medication considerations in older adults. Soc Sci Res Netw. 2025. https:\/\/doi.org\/10.2139\/ssrn.5389209.","journal-title":"Soc Sci Res Netw."},{"key":"3702_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae380","author":"S Liabeuf","year":"2025","unstructured":"Liabeuf S, Minutolo R, Floege J, Zoccali C. The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations. Clin Kidney J. 2025. https:\/\/doi.org\/10.1093\/ckj\/sfae380.","journal-title":"Clin Kidney J."},{"key":"3702_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae250","author":"F Begum","year":"2024","unstructured":"Begum F, Chang K, Kapoor K, et al. Semaglutide-associated kidney injury. Clin Kidney J. 2024. https:\/\/doi.org\/10.1093\/ckj\/sfae250.","journal-title":"Clin Kidney J."},{"key":"3702_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fmed.2022.769329","volume":"15","author":"IL Noronha","year":"2022","unstructured":"Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM. Glomerular filtration in the aging population. Front Med (Lausanne). 2022;15:9. https:\/\/doi.org\/10.3389\/fmed.2022.769329.","journal-title":"Front Med (Lausanne)."},{"key":"3702_CR55","unstructured":"Varghese D, Patel P. Polypharmacy. 2026. PubMed PMID: 30422548."},{"issue":"3","key":"3702_CR56","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","volume":"12","author":"F Pazan","year":"2021","unstructured":"Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021;12(3):443\u201352. https:\/\/doi.org\/10.1007\/s41999-021-00479-3.","journal-title":"Eur Geriatr Med."},{"issue":"2","key":"3702_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/jmh.JMH_87_17","volume":"9","author":"S Hosseini","year":"2018","unstructured":"Hosseini S, Zabihi A, Jafarian Amiri S, Bijani A. Polypharmacy among the elderly. J Midlife Health. 2018;9(2):97. https:\/\/doi.org\/10.4103\/jmh.JMH_87_17.","journal-title":"J Midlife Health."},{"issue":"11","key":"3702_CR58","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1111\/dom.15918","volume":"26","author":"YW Pai","year":"2024","unstructured":"Pai YW, Chen IC, Lin JF, et al. Association of sodium\u2013glucose cotransporter 2 inhibitors with risk of incident dementia and all-cause mortality in older patients with type 2 diabetes: a retrospective cohort study using the TriNetX US collaborative networks. Diabetes Obes Metab. 2024;26(11):5420\u201330. https:\/\/doi.org\/10.1111\/dom.15918.","journal-title":"Diabetes Obes Metab."},{"issue":"Suppl 3","key":"3702_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/alz70857_101831","volume":"21","author":"A Sarwal","year":"2025","unstructured":"Sarwal A, Singh R, Wei G, Hartsell SE, Nevers MR, Katkam N, et al. Risk of Alzheimer\u2019s disease and Alzheimer\u2019s disease-related dementias with liraglutide compared to semaglutide and dulaglutide in veterans with type 2 diabetes: an emulated clinical trial observational study. Alzheimer Dementia. 2025;21(Suppl 3):e101831. https:\/\/doi.org\/10.1002\/alz70857_101831.","journal-title":"Alzheimer Dementia."},{"key":"3702_CR60","doi-asserted-by":"publisher","first-page":"254248232513886","DOI":"10.1177\/25424823251388650","volume":"9","author":"MA AbuAlrob","year":"2025","unstructured":"AbuAlrob MA, Itbaisha A, Abujwaid YK, Abulehia A, Hussein A, Mesraoua B. Exploring the neuroprotective role of GLP-1 agonists against Alzheimer\u2019s disease: real-world evidence from a propensity-matched cohort. J Alzheimer Dis Rep. 2025;9:25424823251388650. https:\/\/doi.org\/10.1177\/25424823251388650.","journal-title":"J Alzheimer Dis Rep."},{"key":"3702_CR61","unstructured":"Novo Nordisk. Semaglutide did not demonstrate superiority in slowing progression of Alzheimer\u2019s disease in EVOKE and EVOKE+ trials [Internet]. 2025 Nov 24 [cited 2026 Apr 24]. Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-details.html?id=916462"},{"issue":"1","key":"3702_CR62","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3233\/ADR-230181","volume":"8","author":"Y Liang","year":"2024","unstructured":"Liang Y, Dor\u00e9 V, Rowe CC, Krishnadas N. Clinical evidence for GLP-1 receptor agonists in Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis Rep. 2024;8(1):777\u201389. https:\/\/doi.org\/10.3233\/ADR-230181.","journal-title":"J Alzheimers Dis Rep."},{"issue":"1","key":"3702_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, et al. Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17(1):14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7.","journal-title":"Alzheimers Res Ther."},{"key":"3702_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943","author":"R Loomba","year":"2024","unstructured":"Loomba R, Neuschwander-Tetri BA, Sanyal AJ, et al. Tirzepatide for metabolic dysfunction\u2013associated steatohepatitis with fibrosis (SYNERGY-NASH). N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med."},{"issue":"21","key":"3702_CR65","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis. N Engl J Med. 2025;392(21):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa2413258.","journal-title":"N Engl J Med"},{"key":"3702_CR66","unstructured":"U.S. Food and Drug Administration. FDA approves tirzepatide for treatment of moderate to severe obstructive sleep apnea in adults with obesity [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Mar 6]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-medication-obstructive-sleep-apnea"},{"key":"3702_CR67","doi-asserted-by":"publisher","DOI":"10.12788\/jfp.0394","author":"J Champlain","year":"2022","unstructured":"Champlain J. Practical considerations for use of insulin\/glucagon-like peptide 1 receptor agonist combinations in older adults with type 2 diabetes. J Fam Pract. 2022. https:\/\/doi.org\/10.12788\/jfp.0394.","journal-title":"J Fam Pract."},{"issue":"1","key":"3702_CR68","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/metabo15010049","volume":"15","author":"AJ Sinclair","year":"2025","unstructured":"Sinclair AJ, Abdelhafiz AH. The use of SGLT-2 inhibitors and GLP-1RA in frail older people with diabetes: a personalised approach is required. Metabolites. 2025;15(1):49. https:\/\/doi.org\/10.3390\/metabo15010049.","journal-title":"Metabolites."},{"issue":"3","key":"3702_CR69","doi-asserted-by":"publisher","first-page":"289","DOI":"10.5853\/jos.2025.00584","volume":"27","author":"Z Lin","year":"2025","unstructured":"Lin Z, Li Z, Jia Q. Glucagon-like peptide-1 receptor agonists in the prevention of ischemic stroke: therapeutic potential and mechanisms. J Stroke. 2025;27(3):289\u2013301. https:\/\/doi.org\/10.5853\/jos.2025.00584.","journal-title":"J Stroke."},{"issue":"7","key":"3702_CR70","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw Open. 2024;7(7):e2421305. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21305.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"3702_CR71","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/jnci\/djae260","volume":"117","author":"L Wang","year":"2025","unstructured":"Wang L, Wang Q, Li L, Kaelber DC, Xu R. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. JNCI J Natl Cancer Inst. 2025;117(3):476\u201385. https:\/\/doi.org\/10.1093\/jnci\/djae260.","journal-title":"JNCI J Natl Cancer Inst."},{"issue":"Suppl\u202f1","key":"3702_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/alz.073346","volume":"72","author":"T Wang","year":"1802","unstructured":"Wang T, Buse JB, Pate V, St\u00fcrmer T. Liraglutide as a potential drug repurposing candidate for Alzheimer\u2019s disease and related dementia: real world evidence. Diabetes. 1802;72(Suppl\u202f1):1802-PUB. https:\/\/doi.org\/10.1002\/alz.073346.","journal-title":"Diabetes"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03702-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03702-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:16:39Z","timestamp":1790655399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03702-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3702"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03702-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna Geraldina Pendrey, Javier Francisco Sevilla Martir, Jennyfer Alejandra Rivera Sierra, Fernando Alberto Alvarez Lobo, Eblin Jackeline Rios Herrera, and Yolanda Mar\u00eda Fernandez Mu\u00f1oz declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}